{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:47Z","timestamp":1786985087841,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.beem.2014.08.006","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T22:30:33Z","timestamp":1409092233000},"page":"205-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The attenuated\/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Carla E.M.","family":"Hollak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2014.08.006_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","article-title":"Lysosomal storage diseases","volume":"60","author":"Neufeld","year":"1991","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.beem.2014.08.006_bib2","article-title":"Gaucher disease: phenotypic and genetic variation","author":"Grabowski","year":"2006"},{"key":"10.1016\/j.beem.2014.08.006_bib3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.beem.2014.08.006_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10545-014-9718-3","article-title":"Treatment of lysosomal storage disorders: successes and challenges","volume":"37","author":"Hollak","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib6","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/brain\/awq198","article-title":"Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study","volume":"133","author":"Biegstraaten","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.beem.2014.08.006_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2014.08.006_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gte.1997.1.5","article-title":"Gaucher disease: gene frequencies and genotype\/phenotype correlations","volume":"1","author":"Grabowski","year":"1997","journal-title":"Genet Test"},{"key":"10.1016\/j.beem.2014.08.006_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1172-7-17","article-title":"Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula","volume":"7","author":"Giraldo","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib11","first-page":"273","article-title":"Gaucher disease in Latin America. A report from the gaucher disease international registry and the Latin American group for gaucher disease","volume":"72","author":"Drelichman","year":"2012","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.beem.2014.08.006_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/qjmed\/hch036","article-title":"Twin pairs showing discordance of phenotype in adult Gaucher's disease","volume":"97","author":"Lachmann","year":"2004","journal-title":"QJM"},{"key":"10.1016\/j.beem.2014.08.006_bib13","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1001\/archinternmed.2010.302","article-title":"Type 1 Gaucher disease: significant disease manifestations in \u201casymptomatic\u201d homozygotes","volume":"170","author":"Balwani","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2014.08.006_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.beem.2014.08.006_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/qjmed\/93.4.237","article-title":"Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features","volume":"93","author":"Lachmann","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.beem.2014.08.006_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","article-title":"An overview on bone manifestations in Gaucher disease","volume":"160","author":"Mikosch","year":"2010","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.beem.2014.08.006_bib17","first-page":"158","article-title":"Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and\/or enzyme replacement therapy","volume":"2","author":"Kauli","year":"2000","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.beem.2014.08.006_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10545-011-9313-9","article-title":"Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy","volume":"34","author":"Lo","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib19","doi-asserted-by":"crossref","first-page":"150450","DOI":"10.1155\/2011\/150450","article-title":"Gaucher disease and cancer: concept and controversy","volume":"2011","author":"Choy","year":"2011","journal-title":"Int J Cell Biol"},{"key":"10.1016\/j.beem.2014.08.006_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1750-1172-9-45","article-title":"Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes","volume":"9","author":"Orenstein","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bcmd.2009.12.006","article-title":"Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study","volume":"44","author":"Boomsma","year":"2010","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib22","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/14656566.9.11.1987","article-title":"Imiglucerase and its use for the treatment of Gaucher's disease","volume":"9","author":"Weinreb","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.beem.2014.08.006_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.beem.2014.08.006_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","article-title":"Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring","volume":"31","author":"Cox","year":"2008","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.beem.2014.08.006_bib25","first-page":"77","article-title":"Oral small molecule therapy for lysosomal storage diseases","volume":"11","author":"Weinreb","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.beem.2014.08.006_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4years of treatment","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","author":"van Dussen","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcmd.2010.10.010","article-title":"Potential biomarkers of osteonecrosis in Gaucher disease","volume":"46","author":"Pavlova","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beem.2014.08.006_bib30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2141.2012.09175.x","article-title":"Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years","volume":"158","author":"Hollak","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beem.2014.08.006_bib31","unstructured":"Desnick RJ, Ioannou YA, Eng CM, et\u00a0al. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill. p. 20013733\u20133774."},{"key":"10.1016\/j.beem.2014.08.006_bib32","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2014.08.006_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib34","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2014.08.006_bib35","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.beem.2014.08.006_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2014.08.006_bib37","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.beem.2014.08.006_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A\u00a0systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.beem.2014.08.006_bib39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.beem.2014.08.006_bib40","series-title":"Fabry disease in females: clinical characteristics and effects of enzyme replacement therapy","author":"Deegan","year":"2006"},{"key":"10.1016\/j.beem.2014.08.006_bib41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.08.006_bib42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10545-011-9447-9","article-title":"Prevalence of symptoms in female Fabry disease patients: a case-control survey","volume":"35","author":"Bouwman","year":"2012","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.beem.2014.08.006_bib44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.08.006_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.08.006_bib46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","article-title":"Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications","volume":"43","author":"Meehan","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2014.08.006_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.08.006_bib49","doi-asserted-by":"crossref","first-page":"c43","DOI":"10.1159\/000320903","article-title":"Blood pressure, proteinuria and nephropathy in Fabry disease","volume":"118","author":"Jain","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.beem.2014.08.006_bib50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11916-013-0365-4","article-title":"Fabry disease: a rare cause of neuropathic pain","volume":"17","author":"Biegstraaten","year":"2013","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.beem.2014.08.006_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CRD.0b013e31818adc50","article-title":"Fabry disease: cardiac manifestations and therapeutic options","volume":"17","author":"Pierre-Louis","year":"2009","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.beem.2014.08.006_bib52","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry's disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.beem.2014.08.006_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.08.006_bib54","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2014.08.006_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.beem.2014.08.006_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2014.08.006_bib57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.beem.2014.08.006_bib58","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.beem.2014.08.006_bib59","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beem.2014.08.006_bib60","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.beem.2014.08.006_bib61","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso) Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PloS one"},{"key":"10.1016\/j.beem.2014.08.006_bib62","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","article-title":"Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2013the Fabry Outcome Survey","volume":"103","author":"Hughes","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.08.006_bib63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1651-2227.2008.00649.x","article-title":"Early therapeutic intervention in females with Fabry disease?","volume":"97","author":"Hughes","year":"2008","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.beem.2014.08.006_bib64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib65","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In\u00a0vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.beem.2014.08.006_bib66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/GIM.0b013e3181f6e676","article-title":"Therapeutic goals in the treatment of Fabry disease","volume":"12","author":"Mehta","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2014.08.006_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2014.08.006_bib68","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.beem.2014.08.006_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-8-29","article-title":"Cost-effectiveness of enzyme replacement therapy for Fabry disease","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages","volume":"37","author":"Rombach","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib71","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"2","author":"El Dib","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beem.2014.08.006_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2014.08.006_bib73","unstructured":"NJ W, KP. Introduction: a 20th anniversary celebration: History and accomplishments of the ICGG Gaucher Registry. Mol Ther."},{"key":"10.1016\/j.beem.2014.08.006_bib74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-6-16","article-title":"Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders","volume":"6","author":"Hollak","year":"2011","journal-title":"Orphanet J Rare Dis"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X14000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:49:06Z","timestamp":1761497346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X14000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1521690X14000979"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2014.08.006","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The attenuated\/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2014.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}